Immunotherapy

Oral immunotherapy appeared effective and well-tolerated by children with hazelnut allergy, according to a retrospective study published in Annals of Allergy, Asthma & Immunology.

Poor quality of life was the primary reason why 9.3% of families pursued peanut oral immunotherapy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

As families and health care providers struggle to manage food allergies, 2021 saw significant advances in research and treatment. Here are our top 10 stories about developments and improvements benefitting these patients.

Most patients with severe cow’s milk allergy can be safely desensitized to substantial levels of baked milk through baked milk oral immunotherapy, according to a study published in The Journal of Allergy and Clinical Immunology.

In this video, Sara Tolaney, MD, MPH, assistant professor of medicine at Harvard Medical School and a breast medical oncologist with Dana-Farber Cancer Institute, discusses research being presented at the symposium.

A panel of experts has compiled 10 tips to help physicians, patients and their families optimize the use of the oral immunotherapy Palforzia — the first FDA-approved treatment for peanut allergy in children aged 4 to 17 years.

John F. de Groot, MD, has been appointed chief of the neuro-oncology division at University of California, San Francisco.

Emese Zsiros, MD, PhD, has been promoted to lead the department of gynecologic oncology at Roswell Park Comprehensive Cancer Center.

FDA approvals of immunotherapies are among several exciting developments during the past couple of years in the field of upper gastrointestinal cancers, according to a speaker at Chemotherapy Foundation Symposium.

Practice type may significantly influence providers’ choice of first-line therapy for metastatic renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.